H.C. Wainwright raised the firm’s price target on VYNE Therapeutics to $28 from $1.50 and keeps a Buy rating on the shares following the one-for-18 reverse stock split. The analyst expects the company’s pipeline to expand shortly with candidate selection for VYN202, and option exercise with VYNE’s license partner Tay Pharma.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYNE:
- VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
- VYNE Therapeutics regains compliance with Nasdaq minimum bid price rule
- VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
- VYNE Therapeutics announces results from Phase 1a trial of VYN201
- VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201